BSC® Solutions
VOICES
Explore our FDA-focused solution areas to see how we support medical device and pharmaceutical companies across regulatory pathways and product types, from early strategy through approval-ready submissions.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 204 54" xmlns="http://www.w3.org/2000/svg"><g d="M 184.738 48 C 174.462 48 169.702 40.916 169.702 27.168 C 169.702 12.972 174.77 6 185.242 6 C 193.39 6 197.87 10.2 198.934 19.16 L 191.85 20.112 C 191.43 14.792 189.106 12.636 185.13 12.636 C 178.466 12.636 176.926 18.656 176.926 26.72 C 176.926 37.136 179.502 41.364 185.018 41.364 C 189.106 41.364 191.514 39.04 192.046 33.076 L 199.102 33.944 C 198.066 43.296 193.11 48 184.738 48 Z M 155.083 48 C 147.187 48 141.699 43.576 141.223 34.504 L 148.363 33.692 C 148.671 39.404 151.135 41.728 155.139 41.728 C 158.527 41.728 160.627 40.048 160.627 36.828 C 160.627 32.432 156.819 31.088 152.619 29.66 C 147.355 27.868 141.391 25.852 141.391 17.536 C 141.391 9.752 146.599 6 154.355 6 C 162.419 6 166.899 10.004 167.431 18.6 L 160.319 19.384 C 160.067 14.316 158.107 12.272 154.131 12.272 C 150.827 12.272 148.615 13.728 148.615 17.032 C 148.615 21.344 152.339 22.632 156.147 23.92 C 162.027 25.908 167.795 27.812 167.795 36.044 C 167.795 43.632 162.923 48 155.083 48 Z M 113.5 47.075 L 113.5 6.923 L 127.864 6.923 C 134.864 6.923 138.476 10.563 138.476 16.947 C 138.476 21.063 136.992 24.311 133.772 25.935 C 137.44 27.195 139.148 30.471 139.148 35.231 C 139.148 42.455 135.228 47.075 128.396 47.075 Z M 120.612 40.439 L 127.248 40.439 C 130.216 40.439 131.952 38.479 131.952 34.615 C 131.952 31.031 130.356 28.903 127.332 28.903 L 120.612 28.903 Z M 120.612 23.499 L 126.884 23.499 C 129.712 23.499 131.308 21.483 131.308 18.235 C 131.308 14.651 129.348 13.559 126.996 13.559 L 120.612 13.559 Z M 93.788 45.234 L 103.096 45.234 C 82.677 45.234 79.944 9 64.86 9 C 49.776 9 47.144 45.234 24.422 45.234 L 0 45.234 M 0.5 45.142 C 35.832 45.142 29.292 0 47.142 0 C 64.992 0 60.655 45.142 94.286 45.142" fill="transparent" height="48px" id="iFqsXxQ2X" transform="translate(2 3)" width="199.10199966430665px"><path d="M 71.238 42 C 60.962 42 56.202 34.916 56.202 21.168 C 56.202 6.972 61.27 0 71.742 0 C 79.89 0 84.37 4.2 85.434 13.16 L 78.35 14.112 C 77.93 8.792 75.606 6.636 71.63 6.636 C 64.966 6.636 63.426 12.656 63.426 20.72 C 63.426 31.136 66.002 35.364 71.518 35.364 C 75.606 35.364 78.014 33.04 78.546 27.076 L 85.602 27.944 C 84.566 37.296 79.61 42 71.238 42 Z M 41.583 42 C 33.687 42 28.199 37.576 27.723 28.504 L 34.863 27.692 C 35.171 33.404 37.635 35.728 41.639 35.728 C 45.027 35.728 47.127 34.048 47.127 30.828 C 47.127 26.432 43.319 25.088 39.119 23.66 C 33.855 21.868 27.891 19.852 27.891 11.536 C 27.891 3.752 33.099 0 40.855 0 C 48.919 0 53.399 4.004 53.931 12.6 L 46.819 13.384 C 46.567 8.316 44.607 6.272 40.631 6.272 C 37.327 6.272 35.115 7.728 35.115 11.032 C 35.115 15.344 38.839 16.632 42.647 17.92 C 48.527 19.908 54.295 21.812 54.295 30.044 C 54.295 37.632 49.423 42 41.583 42 Z M 0 41.075 L 0 0.923 L 14.364 0.923 C 21.364 0.923 24.976 4.563 24.976 10.947 C 24.976 15.063 23.492 18.311 20.272 19.935 C 23.94 21.195 25.648 24.471 25.648 29.231 C 25.648 36.455 21.728 41.075 14.896 41.075 Z M 7.112 34.439 L 13.748 34.439 C 16.716 34.439 18.452 32.479 18.452 28.615 C 18.452 25.031 16.856 22.903 13.832 22.903 L 7.112 22.903 Z M 7.112 17.499 L 13.384 17.499 C 16.212 17.499 17.808 15.483 17.808 12.235 C 17.808 8.651 15.848 7.559 13.496 7.559 L 7.112 7.559 Z" fill="rgb(0, 0, 0)" height="42px" id="TmpG5bKj6" transform="translate(113.5 6)" width="85.60199966430665px"/><path d="M 93.788 36.234 L 103.096 36.234 C 82.677 36.234 79.944 0 64.86 0 C 49.776 0 47.144 36.234 24.422 36.234 L 0 36.234" fill="transparent" height="36.23400000000001px" id="hDuxK1Epu" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="3.861" stroke="rgb(0, 0, 0)" transform="translate(0 9)" width="103.096px"/><path d="M 0 45.142 C 35.332 45.142 28.792 0 46.642 0 C 64.492 0 60.155 45.142 93.786 45.142" fill="transparent" height="45.141999999999996px" id="l4coILr9Z" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="3.861" stroke="rgb(0, 0, 0)" transform="translate(0.5 0)" width="93.786px"/></g></svg>)
Understanding E9(R1) Addendum: A Guide to Estimands
Master the E9(R1) Addendum on estimands. Learn how this framework enhances clinical trial precision, aligns objectives, and ensures regulatory compliance.
Understanding E9(R1) Addendum: A Guide to Estimands
Master the E9(R1) Addendum on estimands. Learn how this framework enhances clinical trial precision, aligns objectives, and ensures regulatory compliance.
Understanding E9(R1) Addendum: A Guide to Estimands
Master the E9(R1) Addendum on estimands. Learn how this framework enhances clinical trial precision, aligns objectives, and ensures regulatory compliance.
Published on Jan 7, 2026
•
•
7 min read time
Introduction
In the complex landscape of clinical trials, precision is paramount. A recurring challenge in trial design and analysis has been the misalignment between the clinical question posed and the statistical analysis performed. This disconnect often stems from how we handle intercurrent events—events like treatment discontinuation or the use of rescue medication that occur after randomization and affect the interpretation of the outcome.
The International Council for Harmonisation (ICH) addressed this critical gap with the E9(R1) Addendum to Statistical Principles for Clinical Trials. This guidance introduces a structured framework centered on "estimands."
This post dissects the E9(R1) Addendum, explaining its purpose and key components. We will explore how this framework impacts trial design and analysis, ensuring that your clinical objectives align perfectly with your statistical methods for robust regulatory compliance.
The Purpose of E9(R1)
The primary goal of the E9(R1) Addendum is to improve transparency and alignment in clinical trials. Before this guidance, protocols often vaguely defined "intention-to-treat" (ITT) principles without explicitly stating how to handle data affected by intercurrent events. This ambiguity led to inconsistencies in how treatment effects were estimated and interpreted.
The Addendum mandates a disciplined process to define exactly what needs to be estimated before determining how to estimate it. It enforces a dialogue between clinicians and statisticians early in the study design phase. By clarifying the treatment effect of interest upfront, we ensure that the trial design, conduct, and analysis are all synchronized to answer the specific clinical question relevant to patients, physicians, and regulators.
Key Components: The Estimand Framework
An estimand is a precise description of the treatment effect that is to be estimated. The E9(R1) framework breaks an estimand down into five essential attributes. Defining these attributes provides a blueprint for the entire trial strategy.
The Treatment
This attribute defines exactly what the experimental treatment and the control treatment involve. It is not just the drug itself but the entire treatment regimen. This might include background medication, administration instructions, or permitted rescue therapies. Precision here prevents ambiguity regarding what is actually being compared.The Population
This defines the group of patients targeted by the clinical question. While this usually aligns with the inclusion/exclusion criteria of the trial, it specifies the population for whom the treatment effect is being estimated. For instance, are we interested in the effect on all randomized patients, or only a specific subset defined by a biomarker?The Variable
This is the specific endpoint to be obtained for each patient. It includes the type of variable (e.g., change from baseline in blood pressure) and the timing of the assessment (e.g., at Week 24). It is crucial to define exactly how this variable is measured.Intercurrent Events
This is the most transformative aspect of the E9(R1) Addendum. It requires the protocol to list potential intercurrent events (e.g., death, discontinuation, use of additional medication) and explicitly state how each will be handled in the analysis. The guidance offers five strategies for handling these events:
Treatment Policy Strategy: The occurrence of the intercurrent event is irrelevant; we use the data regardless (often consistent with ITT).
Composite Variable Strategy: The intercurrent event is integrated into the endpoint itself (e.g., "failure" includes lack of efficacy OR discontinuation).
Hypothetical Strategy: We estimate the effect in a scenario where the intercurrent event would not occur.
Principal Stratum Strategy: We estimate the effect only in the sub-population of subjects who would not experience the intercurrent event.
While on Treatment Strategy: We assess the response to treatment prior to the occurrence of the intercurrent event.
Population-Level Summary
This defines how the variable will be summarized across the population to compare treatment groups. Examples include the difference in means, the hazard ratio, or the odds ratio.
Impact on Trial Design and Conduct
Implementing the E9(R1) framework is not merely a statistical exercise; it fundamentally shifts how trials are designed and conducted.
Enhanced Protocol Development
The framework demands that the estimand be defined in the protocol before the statistical analysis plan is written. This requires cross-functional collaboration. Clinicians, regulatory experts, and statisticians must agree on the clinical question. This proactive approach reduces the risk of post-hoc disagreements with regulators about how data should be handled.
Data Collection Strategies
Once the strategies for intercurrent events are chosen, they dictate data collection. If a "Treatment Policy" strategy is selected for subjects who discontinue the study drug, the operations team must make every effort to continue collecting efficacy data from those subjects for the duration of the trial. Conversely, if a "Hypothetical" strategy is used, distinct data collection procedures may be required to support the statistical modeling.
Minimizing Missing Data
The framework highlights the distinction between "missing data" and data that are simply not relevant due to an intercurrent event. However, by clearly defining the handling of these events, study teams can better train sites on what data is absolutely critical to retain, thereby reducing preventable missing data and preserving the integrity of the analysis.
Real-World Application: A Diabetes Trial Example
To illustrate the practical application of the Addendum, consider a clinical trial for a new Type 2 diabetes medication comparing a new drug to a placebo. The primary endpoint is the change in HbA1c at Week 24.
The Challenge:
Patients in both groups may require "rescue medication" (e.g., insulin) if their blood sugar becomes dangerously high during the trial. How do we account for this?
Scenario A: The Treatment Policy Strategy
Clinical Question: What is the effect of the treatment regimen regardless of whether rescue medication is used?
Approach: We ignore the start of rescue medication and use the HbA1c value at Week 24 as observed. This reflects a "real-world" effectiveness perspective.
Impact: We must collect HbA1c data at Week 24 even if the patient started insulin at Week 12.
Scenario B: The Composite StrategyClinical Question: Does the treatment allow patients to achieve glycemic control without needing rescue medication?
Approach: The endpoint is redefined. A patient is considered a "responder" only if they achieve the HbA1c target AND do not require rescue medication. If they take rescue medication, they are classified as a non-responder.
Impact: The variable changes from a continuous measure (change in HbA1c) to a binary one (responder/non-responder), fundamentally changing the sample size calculation and analysis.
Scenario C: The Hypothetical StrategyClinical Question: What would be the effect of the drug if rescue medication were not available?
Approach: Data collected after rescue medication initiation is censored. We use statistical modeling (e.g., multiple imputation) to predict what the HbA1c would have been had the rescue medication not been taken.
Impact: This relies heavily on statistical assumptions that must be rigorously justified to regulators.
By selecting the appropriate strategy upfront, the sponsor avoids ambiguity. Without this framework, a sponsor might mix these approaches ad-hoc, leading to a rejected submission.
Sensitivity Analysis: Ensuring Robustness
The E9(R1) Addendum emphasizes that the main estimator (the statistical method aligned with the estimand) must be validated. This is where Sensitivity Analysis becomes critical.
Sensitivity analysis tests the assumptions made in the primary analysis. It asks: "If we change our assumptions slightly, do the results hold up?"
For example, if we use a Hypothetical Strategy and impute missing data based on the assumption that patients behave similarly to those who stayed on treatment, a sensitivity analysis might impute data assuming a "washout" or return to baseline. If the treatment effect remains significant across these different assumptions, the results are considered robust.
This step demonstrates scientific diligence. It proves that the positive outcome is not merely an artifact of a specific statistical method or assumption but a genuine clinical effect.
Conclusion: Strategic Alignment for Success
The E9(R1) Addendum is more than a regulatory requirement; it is a tool for strategic alignment. By rigorously defining estimands, sponsors can ensure that their trials are designed to answer the right questions with precision and clarity.
Adopting this methodical approach minimizes the risk of regulatory setbacks. It ensures that the handling of intercurrent events is scientifically justified and pre-specified, rather than decided post-hoc. For life sciences companies, mastering this framework is essential for navigating the complexities of modern clinical development and achieving successful, data-driven outcomes.
Next StepsReview your current protocols to ensure clear estimand definitions are in place.
Engage your biostatistics and clinical teams early in the design process to discuss intercurrent events.
Consult with regulatory experts to align your chosen strategies with agency expectations for your specific therapeutic area.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Use your preferred LLM to explore BSC®
Use your preferred LLM to explore BSC®